Ortin Global Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Ortin Laboratories hat ein Gesamteigenkapital von ₹97.6M und eine Gesamtverschuldung von ₹60.1M, was einen Verschuldungsgrad von 61.6% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen ₹182.3M bzw. ₹84.7M.

Wichtige Informationen

63.8%

Verhältnis von Schulden zu Eigenkapital

₹18.02m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	₹23.43m
Eigenkapital	₹28.24m
Gesamtverbindlichkeiten	₹38.40m
Gesamtvermögen	₹66.64m

Jüngste Berichte zur Finanzlage

Is Ortin Laboratories (NSE:ORTINLABSS) A Risky Investment?

Dec 27

Here's Why Ortin Laboratories (NSE:ORTINLABSS) Is Weighed Down By Its Debt Load

Sep 15

Recent updates

Here's Why I Think Ortin Laboratories (NSE:ORTINLABSS) Might Deserve Your Attention Today

Jan 24

Is Ortin Laboratories (NSE:ORTINLABSS) A Risky Investment?

Dec 27

Ortin Laboratories Limited (NSE:ORTINLABSS) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Nov 30

Here's Why Ortin Laboratories (NSE:ORTINLABSS) Is Weighed Down By Its Debt Load

Sep 15

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: ORTINLABDie kurzfristigen Aktiva des Unternehmens (₹63.4M) übersteigen seine kurzfristigen Passiva (₹20.4M).

Langfristige Verbindlichkeiten: ORTINLABDie kurzfristigen Vermögenswerte des Unternehmens (₹37.2M) übersteigen seine langfristigen Verbindlichkeiten (₹29.1M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: ORTINLAB über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: ORTINLAB Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 84.3% auf 61.6% zurückgegangen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: ORTINLAB hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: ORTINLAB hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 16.6% pro Jahr abnimmt

Ortin Global Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is Ortin Laboratories (NSE:ORTINLABSS) A Risky Investment?

Here's Why Ortin Laboratories (NSE:ORTINLABSS) Is Weighed Down By Its Debt Load

Recent updates

Ortin Global Limited, Annual General Meeting, Sep 30, 2024

First quarter 2025 earnings released: ₹0.13 loss per share (vs ₹0.02 profit in 1Q 2024)

New minor risk - Share price stability

Ortin Global Limited to Report Q1, 2025 Results on Aug 13, 2024

Ortin Laboratories Limited Announces Resignation of Divya Purswani as Company Secretary and Compliance Officer

Full year 2024 earnings released: ₹9.89 loss per share (vs ₹0.12 loss in FY 2023)

Ortin Laboratories Limited to Report Q4, 2024 Results on May 30, 2024

Third quarter 2024 earnings released: ₹3.43 loss per share (vs ₹0.56 profit in 3Q 2023)

Ortin Laboratories Limited Appoints Divya Purswani as Company Secretary and Compliance Officer

Ortin Laboratories Limited to Report Q3, 2024 Results on Feb 13, 2024

Now 22% overvalued after recent price rise

Insufficient new directors

Second quarter 2024 earnings released

Ortin Laboratories Limited Announces Executive Changes

Ortin Laboratories Limited Appointment of Harish Sharma as Company Secretary

Ortin Laboratories Limited, Annual General Meeting, Sep 30, 2023

First quarter 2024 earnings released

Ortin Laboratories Limited to Report Q1, 2024 Results on Aug 14, 2023

Drugs Control Administration, Government of Telangana Cancels Manufacturing License of Ortin Laboratories Limited

Ortin Laboratories Limited Announces Resignation of Nitesh Kumar Sharma as Company Secretary/Compliance Officer

New minor risk - Share price stability

Full year 2023 earnings released: ₹0.08 loss per share (vs ₹0.49 loss in FY 2022)

Third quarter 2023 earnings released: EPS: ₹0.56 (vs ₹0.11 loss in 3Q 2022)

Ortin Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023

Ortin Laboratories Limited Announces Resignation of J R K Panduranga Rao as Independent Director

Second quarter 2023 earnings released: EPS: ₹0.01 (vs ₹0.07 in 2Q 2022)

Ortin Laboratories Limited to Report First Half, 2023 Results on Nov 14, 2022

Ortin Laboratories Limited Announces Cessation of Bh. Satyanarayana Raju and G. Venkata Ramana, Directors

Ortin Laboratories Limited, Annual General Meeting, Sep 30, 2022

First quarter 2023 earnings released: ₹0.05 loss per share (vs ₹0.11 profit in 1Q 2022)

Ortin Laboratories Limited to Report Q1, 2023 Results on Aug 13, 2022

Full year 2022 earnings released: ₹0.49 loss per share (vs ₹1.16 profit in FY 2021)

Ortin Laboratories Limited to Report Q4, 2022 Results on May 30, 2022

Whole Time Director Sanka Mohan Murthy has left the company

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹1.16 (vs ₹0.69 loss in FY 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Ortin Laboratories Limited to Report Q3, 2021 Results on Feb 13, 2021

Here's Why I Think Ortin Laboratories (NSE:ORTINLABSS) Might Deserve Your Attention Today

Investor sentiment improved over the past week

Ortin Laboratories Limited Appoints Mr. S. Srinivas Kumar as CFO

Investor sentiment improved over the past week

New 90-day high: ₹30.00

Is Ortin Laboratories (NSE:ORTINLABSS) A Risky Investment?

Ortin Laboratories Limited Appoints Pottur Sujatha as Additional Director

Market bids up stock over the past week

Ortin Laboratories Limited (NSE:ORTINLABSS) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

New 90-day high: ₹23.15

First quarter earnings released

Here's Why Ortin Laboratories (NSE:ORTINLABSS) Is Weighed Down By Its Debt Load

Ortin Laboratories Limited to Report Q1, 2021 Results on Sep 15, 2020

Ortin Laboratories Limited to Report Q4, 2020 Results on Jul 30, 2020

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen